Janssen GB, Penninks AH, Knippels LM, van Zijverden M, Spanhaak S (2008). "The evaluation of the immunomodulating properties of ERA-63 a pharmaceutical with estrogenic activity". Toxicol. Lett. 180 (3): 196–201. doi:10.1016/j.toxlet.2008.06.857. PMID18602456.
van Vollenhoven RF, Houbiers JG, Buttgereit F, In 't Hout J, Boers M, Leij S, Kvien TK, Dijkmans BA, Szczepański L, Szombati I, Sierakowski S, Miltenburg AM (2010). "The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine". Arthritis Rheum. 62 (2): 351–8. doi:10.1002/art.27196. PMID20112368.
Janssen GB, Penninks AH, Knippels LM, van Zijverden M, Spanhaak S (2008). "The evaluation of the immunomodulating properties of ERA-63 a pharmaceutical with estrogenic activity". Toxicol. Lett. 180 (3): 196–201. doi:10.1016/j.toxlet.2008.06.857. PMID18602456.
van Vollenhoven RF, Houbiers JG, Buttgereit F, In 't Hout J, Boers M, Leij S, Kvien TK, Dijkmans BA, Szczepański L, Szombati I, Sierakowski S, Miltenburg AM (2010). "The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine". Arthritis Rheum. 62 (2): 351–8. doi:10.1002/art.27196. PMID20112368.